Thymoquinone protects cultured hippocampal and human induced pluripotent stem cells-derived neurons against α-synuclein-induced synapse damage

Neuroscience Letters

Volumn 570, Issue , 2014, Pages 126-131

  Alhebshi, A H ^a   Odawara, A ^a   Gotoh, M ^a   Suzuki, I ^a  

^a TOKYO UNIVERSITY OF TECHNOLOGY   (Japan)

Author keywords

Cultured rat hippocampal neurons; Human induced pluripotent stem cell derived neurons; Synapse damage; Thymoquinone; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; FLUORESCENT DYE; SYNAPTOPHYSIN; THYMOQUINONE; BENZOQUINONE DERIVATIVE; NEUROPROTECTIVE AGENT;

ANIMAL TISSUE; CONTROLLED STUDY; CYTOTOXICITY; DIFFUSE LEWY BODY DISEASE; EMBRYO; HIPPOCAMPUS; HUMAN; HUMAN CELL; MISSENSE MUTATION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; NOTE; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RAT; SYNAPSE VESICLE; ACTION POTENTIAL; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; NERVE CELL; PHYSIOLOGY; PRIMARY CELL CULTURE; SYNAPSE; TOXICITY; WISTAR RAT;

ACTION POTENTIALS; ALPHA-SYNUCLEIN; ANIMALS; BENZOQUINONES; CELLS, CULTURED; HIPPOCAMPUS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MUTATION; NEURONS; NEUROPROTECTIVE AGENTS; PRIMARY CELL CULTURE; RATS, WISTAR; SYNAPSES; SYNAPTIC VESICLES; SYNAPTOPHYSIN;

EID: 84900846673     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.09.049     Document Type: Note

References (33)

1. Galvin J.E., Uryu K., Lee V.M., Trojanowski J.Q. Axon pathology in Parkinson's disease and lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13450-13455.
2. Pacheco C., Aguayo L.G., Opazo C. An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brain. Front. Physiol. 2012, 297:3389-3399.
3. Kramer M.L., Schulz-Schaeffer W.J. Presynaptic a-synuclein aggregates, not lewy bodies, cause neurodegeneration in dementia with lewy bodies. J. Neurosci. 2007, 27:1405-1410.
4. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998, 21:249-254.
5. Kazantsev A.G., Kolchinsky A.M. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch. Neurol. 2008, 65:1577-1581.
6. Brundin P., Melki R., Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 2010, 11:301-307.
7. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
8. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29:3365-3373.
9. Bate B.C., Williams A. Ethanol protects cultured neurons against amyloid-β and α-synuclein-induced synapse damage. Neuropharmacology 2011, 61:1406-1412.
10. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., Sidransky E., Grabowski G.A., Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
11. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Sudhof T.C. α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
12. Devine M.J., Ryten M., Vodicka P., Thomson A.J., Burdon T., Houlden H., Cavaleri F., Nagano M., Drummond N.J., Taanman J.W., Schapira A.H., Gwinn K., Hardy J., Lewis P.A., Kunathb T. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat. Commun. 2011, 440(2):1-10.
13. Linta L., Stockmann M., Boeckers T.M., Kleger A., Liebau S. The potential of iPS cells in synucleinopathy research. Stem Cells Int. 2012, 2012:629230.
14. Ahmad A., Husain A., Mujeeb M., Khan S.A., Najmi A.K., Siddique N.A., Damanhouri Z.A., Anwar F. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac. J. Trop. Biomed. 2013, 3:337-352.
15. Woo C.C., Kumar A.P., Sethi G., Tan K.H.B. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem. Pharmacol. 2012, 83:443-451.
16. Ismail M., Al-Naqeep G., Chan K.W. Nigella sativa thymoquinone-rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats. Free Radic. Biol. Med. 2010, 48:664-672.
17. Peng L., Liu A., Shen Y., Xu H.Z., Yang S.Z., Ying X.Z., Liao W., Liu H.X., Lin Z.Q., Chen Q.Y., Cheng S.W., Shen W.D. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-κB pathway. Oncol. Rep. 2013, 29:571-578.
18. Radad K., Moldzio R., Taha M., Rausch W.D. Thymoquinone protects dopaminergic neurons against MPP+ and rotenone. Phytother. Res. 2009, 23:696-700.
19. Ullah I., Ullah N., Naseer M.I., Lee H.Y., Kim M.O. Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons. BMC Neurosci. 2012, 13:11.
20. Khan A., Vaibhav K., Javed H., Khan M.M., Tabassum R., Ahmed M.E., Srivastava P., Khuwaja G., Islam F., Siddiqui M.S., Shafi M.M., Islam F. Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Mol. Cell Biochem. 2012, 369:55-65.
21. Al-Majed A.A., Al-Omar F.A., Nagi M.N. Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur. J. Pharmacol. 2006, 543:40-47.
22. Alhebshi A.H., Gotoh M., Suzuki I. Thymoquinone protects cultured rat primary neurons against amyloid β-induced neurotoxicity. Biochem. Biophys. Res. Commun. 2013, 433:362-367.
23. Daly C., Sugimori M., Moreira J.E., Ziff E.B., Llinas R. Synaptophysin regulates clathrin-independent endocytosis of synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6120-6125.
24. Reddy P.H., Mani G., Park B.S., Jacques J., Murdoch G., Whetsell W., Kaye J., Manczak M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimers Dis. 2005, 7:103-117.
25. Bate C., Tayebi M., Salmona M., Diomede L., Williams A. Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro. Neurotox. Res. 2010, 17:203-214.
26. Fujita M., Sugama S., Sekiyama K., Sekigawa A., Tsukui T., Nakai M., Waragai M., Takenouchi T., Takamatsu Y., Wei J., Rockenstein E., Laspada A.R., Masliah E., Inoue S., Hashimoto M.A. β-Synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat. Commun. 2010, 1110:1-9.
27. Cousin M.A., Robinson P.J. Mechanisms of synaptic vesicle recycling illuminated by fluorescent dyes. J. Neurochem. 1999, 73:2227-2239.
28. 1-42. Mol. Neurodegener. 2010, 55:5.
29. Ohtake H., Limprasert P., Fan Y., Onodera O., Kakita A., Takahashi H., Bonner L.T., Tsuang D.W., Murray I.V.J., Lee V.M.-Y., Trojanowski J.Q., Ishikawa A., Idezuka J., Murata M., Toda T., Bird T.D., Leverenz J.B., Tsuji S., La Spada A.R. β-Synuclein gene alterations in dementia with Lewy bodies. Neurology 2004, 63:805-811.
30. Al-Naggar T.B., Gómez-Serranillos M.P., Carretero M.E., Villar A.M. Neuropharmacological activity of N. sativa L. J. Ethnopharmacol. 2003, 88:63-68.
31. Mutabagani A., El-Mahdy S.A.M. A study of the anti-inflammatory activity of Nigella sativa L. and thymoquinone. Saudi Pharm. J. 1997, 5:110-113.
32. Kanter M. Nigella sativa and derived thymoquinone prevents hippocampal neurodegeneration after chronic toluene exposure in rats. Neurochem. Res. 2008, 33:579-588.
33. Alam S.S., Khan Z.I., Mustafa G., Kumar M., Islam F., Bhatnagar A., Ahmad F.J. Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int. J. Nanomed. 2012, 7:5705-5718.